Rhabdoviruses as vaccine platforms for infectious disease and cancer

References

• Agnandji, S. T., Fernandes, J. F., Bache, E. B., Obiang Mba, R. M., Brosnahan, J. S., Kabwende, L., … Kremsner, P. G. (2017). Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial. PLOS Medicine, 14(10), e1002402. doi:10.1371/journal.pmed.1002402
   PubMed Web of Science ®Google Scholar
• Atherton, M. J., Stephenson, K. B., Pol, J., Wang, F., Lefebvre, C., Stojdl, D. F., … Lichty, B. D. (2017). Customized viral immunotherapy for HPV-associated cancer. Cancer Immunology Research, 5(10), 847–859. doi:10.1158/2326-6066.CIR-17-0102
   PubMed Web of Science ®Google Scholar
• Ball, L. A., Pringle, C. R., Flanagan, B., Perepelitsa, V. P., & Wertz, G. W. (1999). Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. Journal of Virology, 73(6), 4705–4712.
   PubMed Web of Science ®Google Scholar
• Betancourt, D., de Queiroz, N. M. G. P., Xia, T., Ahn, J., & Barber, G. N. (2017). Cutting edge: Innate immune augmenting vesicular stomatitis virus expressing zika virus proteins confers protective immunity. Journal of Immunology (Baltimore, Md.: 1950), 198(8), 3023–3028. doi:10.4049/jimmunol.1602180
   PubMed Web of Science ®Google Scholar
• Brandsma, J. L., Shlyankevich, M., Buonocore, L., Roberts, A., Becker, S. M., & Rose, J. K. (2007). Therapeutic efficacy of vesicular stomatitis virus-based E6 vaccination in rabbits. Vaccine, 25(4), 751–762. doi:10.1016/j.vaccine.2006.08.012
   PubMed Web of Science ®Google Scholar
• Bridle, B. W., Boudreau, J. E., Lichty, B. D., Brunellière, J., Stephenson, K., Koshy, S., … Wan, Y. (2009). Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Molecular Therapy: the Journal of the American Society of Gene Therapy, 17(10), 1814–1821. doi:10.1038/mt.2009.154
   PubMed Web of Science ®Google Scholar
• Bridle, B. W., Clouthier, D., Zhang, L., Pol, J., Chen, L., Lichty, B. D., … Wan, Y. (2013). Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. OncoImmunology, 2(8), e26013. doi:10.4161/onci.26013
   PubMed Web of Science ®Google Scholar
• Bridle, B. W., Hanson, S., & Lichty, B. D. (2010). Combining oncolytic virotherapy and tumour vaccination. Cytokine & Growth Factor Reviews, 21(2–3), 143–148. doi:10.1016/j.cytogfr.2010.02.009
   PubMed Web of Science ®Google Scholar
• Bridle, B. W., Stephenson, K. B., Boudreau, J. E., Koshy, S., Kazdhan, N., Pullenayegum, E., … Wan, Y. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(8), 1430–1439. doi:10.1038/mt.2010.98
   PubMed Web of Science ®Google Scholar
• Brun, J., McManus, D., Lefebvre, C., Hu, K., Falls, T., Atkins, H., … Stojdl, D. F. (2010). Identification of genetically modified maraba virus as an oncolytic rhabdovirus. Molecular Therapy: The Journal of the American Society of Gene Therapy, 18(8), 1440–1449. doi:10.1038/mt.2010.103
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. (2017, January 1). 2014-16 Ebola outbreak in West Africa. Retrieved 2017, from November 15.
   Google Scholar
• Chattopadhyay, A., Wang, E., Seymour, R., Weaver, S. C., & Rose, J. K. (2013). A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. Journal of Virology, 87(1), 395–402. doi:10.1128/JVI.01860-12
   PubMed Web of Science ®Google Scholar
• Clarke, D. K., Hendry, R. M., Singh, V., Rose, J. K., Seligman, S. J., Klug, B., … Brighton Collaboration Viral Vector Vaccines Safety Working Group. (2016). Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment. Vaccine, 34(51), 6597–6609. doi:10.1016/j.vaccine.2016.06.071
   PubMed Web of Science ®Google Scholar
• Clarke, D. K., Nasar, F., Chong, S., Johnson, J. E., Coleman, J. W., Lee, M., … Udem, S. A. (2014). Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. Journal of Virology, 88(12), 6690–6701. doi:10.1128/JVI.03441-13
   PubMed Web of Science ®Google Scholar
• Clarke, D. K., Nasar, F., Lee, M., Johnson, J. E., Wright, K., Calderon, P., … Udem, S. A. (2007). Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. Journal of Virology, 81(4), 2056–2064. doi:10.1128/JVI.01911-06
   PubMed Web of Science ®Google Scholar
• Cohen, K. W., & Frahm, N. (2017). Current views on the potential for development of a HIV vaccine. Expert Opinion on Biological Therapy, 17(3), 295–303. doi:10.1080/14712598.2017.1282457
   PubMed Web of Science ®Google Scholar
• Cooper, D., Wright, K. J., Calderon, P. C., Guo, M., Nasar, F., Johnson, J. E., … Clarke, D. K. (2008). Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice. Journal of Virology, 82(1), 207–219. doi:10.1128/JVI.01515-07
   PubMed Web of Science ®Google Scholar
• Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014). Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nature Reviews. Cancer, 14(2), 135–146. doi:10.1038/nrc3670
   PubMed Web of Science ®Google Scholar
• Dye, C. (2014). After 2015: Infectious diseases in a new era of health and development. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 369(1645), 20130426. doi:10.1098/rstb.2013.0426
   PubMed Web of Science ®Google Scholar
• Eyles, J. E., Johnson, J. E., Megati, S., Roopchand, V., Cockle, P. J., Weeratna, R., … Sidhu, M. K. (2013). Nonreplicating vaccines can protect African green monkeys from the memphis 37 strain of respiratory syncytial virus. The Journal of Infectious Diseases, 208(2), 319–329. doi:10.1093/infdis/jit169
   PubMed Web of Science ®Google Scholar
• Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., … Geisbert, T. W. (2007). Effective post-exposure treatment of Ebola infection. PLoS Pathogens, 3(1), e2. doi:10.1371/journal.ppat.0030002
   PubMed Web of Science ®Google Scholar
• FiercePharma. (2017, January 1). China approves domestic Ebola vaccine developed from recent outbreak. Retrieved 2017, from November 15.
   Google Scholar
• Fuchs, J. D., Frank, I., Elizaga, M. L., Allen, M., Frahm, N., Kochar, N., … Ferrara, A. (2015). First-in-human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine (HVTN 090). Open Forum Infectious Diseases, 2(3), ofv082. http://doi.org/10.1093/ofid/ofv082
   PubMed Web of Science ®Google Scholar
• Garbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Möller, P., Wagner, R., … Ströher, U. (2004). Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. Journal of Virology, 78(10), 5458–5465. doi:10.1128/JVI.78.10.5458-5465.2004
   PubMed Web of Science ®Google Scholar
• Geisbert, T. W., & Feldmann, H. (2011). Recombinant vesicular stomatitis virus-based vaccines against Ebola and marburg virus infections. The Journal of Infectious Diseases, 204(suppl. 3), S1075–S1081. http://doi.org/10.1093/infdis/jir34910.1093/infdis/jir349
   PubMed Web of Science ®Google Scholar
• Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., … Kurzrock, R. (2017). Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Molecular Cancer Therapeutics, 16(11), 2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., … Kieny, M.-P. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet, 389(10068), 505–518. doi:10.1016/S0140-6736(16)32621-6
   PubMed Web of Science ®Google Scholar
• Huttner, A., Dayer, J.-A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., … VSV-Ebola Consortium. (2015). The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1/2 trial. The Lancet. Infectious Diseases, 15(10), 1156–1166. doi:10.1016/S1473-3099(15)00154-1
   PubMed Web of Science ®Google Scholar
• Ilett, E., Kottke, T., Thompson, J., Rajani, K., Zaidi, S., Evgin, L., … Vile, R. (2017). Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Therapy, 24(1), 21–30. doi:10.1038/gt.2016.70
   PubMed Web of Science ®Google Scholar
• Johnson, J. E., Nasar, F., Coleman, J. W., Price, R. E., Javadian, A., Draper, K., … Udem, S. A. (2007). Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology, 360(1), 36–49. doi:10.1016/j.virol.2006.10.026
   PubMed Web of Science ®Google Scholar
• Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., … Geisbert, T. W. (2005). Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine, 11(7), 786–790. doi:10.1038/nm1258
   PubMed Web of Science ®Google Scholar
• Kennedy, S. B., Bolay, F., Kieh, M., Grandits, G., Badio, M., Ballou, R., … PREVAIL I Study Group. (2017). Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. The New England Journal of Medicine, 377(15), 1438–1447. doi:10.1056/NEJMoa1614067
   PubMed Web of Science ®Google Scholar
• Khalafallah, M. T., Aboshady, O. A., Moawed, S. A., & Ramadan, M. S. (2017). Ebola virus disease: Essential clinical knowledge. Avicenna Journal of Medicine, 7(3), 96–102. doi:10.4103/ajm.AJM_150_16
   PubMedGoogle Scholar
• Khurana, S., Fuentes, S., Coyle, E. M., Ravichandran, S., Davey, R. T., & Beigel, J. H. (2016). Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nature Medicine, 22(12), 1439–1447. doi:10.1038/nm.4201
   PubMed Web of Science ®Google Scholar
• Kim, D.-S., Dastidar, H., Zhang, C., Zemp, F. J., Lau, K., Ernst, M., … Mahoney, D. J. (2017). Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nature Communications, 8(1), 344. doi:10.1038/s41467-017-00324-x
   PubMed Web of Science ®Google Scholar
• Klein, G. (1966). Tumor antigens. Annual Review of Microbiology, 20, 223–252. Retrieved from http://doi.org/10.1146/annurev.mi.20.100166.001255
   PubMed Web of Science ®Google Scholar
• Kreiter, S., Castle, J. C., Türeci, O., & Sahin, U. (2012). Targeting the tumor mutanome for personalized vaccination therapy. OncoImmunology, 1(5), 768–769. doi:10.4161/onci.19727
   PubMed Web of Science ®Google Scholar
• Lawson, N. D., Stillman, E. A., Whitt, M. A., & Rose, J. K. (1995). Recombinant vesicular stomatitis viruses from DNA. Proceedings of the National Academy of Sciences of the United States of America, 92(10), 4477–4481.10.1073/pnas.92.10.4477
   PubMed Web of Science ®Google Scholar
• Li, S. S., Kochar, N. K., Elizaga, M., Hay, C. M., Wilson, G. J., Cohen, K. W., … NIAID HIV Vaccine Trials Network. (2017). DNA priming increases frequency of T-cell responses to a VSV HIV vaccine with specific enhancement of CD8(+) T-cell responses by IL-12 pDNA. Clinical and Vaccine Immunology : CVI, 24(11), e00263–17. http://doi.org/10.1128/CVI.00263-17
   Google Scholar
• Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., … Schumacher, T. N. M. (2015). High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature Medicine, 21(1), 81–85. doi:10.1038/nm.3773
   PubMed Web of Science ®Google Scholar
• Lo, M. K., Bird, B. H., Chattopadhyay, A., Drew, C. P., Martin, B. E., Coleman, J. D., … Spiropoulou, C. F. (2014). Single-dose replication-defective VSV-based nipah virus vaccines provide protection from lethal challenge in Syrian hamsters. Antiviral Research, 101, 26–29. doi:10.1016/j.antiviral.2013.10.012
   PubMed Web of Science ®Google Scholar
• Marzi, A., Engelmann, F., Feldmann, F., Haberthur, K., Shupert, W. L., Brining, D., … Messaoudi, I. (2013). Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 110(5), 1893–1898. doi:10.1073/pnas.1209591110
   PubMed Web of Science ®Google Scholar
• Marzi, A., Halfmann, P., Hill-Batorski, L., Feldmann, F., Shupert, W. L., Neumann, G., … Kawaoka, Y. (2015). Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates. Science, 348(6233), 439–442. doi:10.1126/science.aaa4919
   PubMed Web of Science ®Google Scholar
• Marzi, A., Hanley, P. W., Haddock, E., Martellaro, C., Kobinger, G., & Feldmann, H. (2016). Efficacy of vesicular stomatitis virus-Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus Makona. The Journal of Infectious Diseases, 214(Suppl. 3), S360–S366. doi:10.1093/infdis/jiw218
   PubMed Web of Science ®Google Scholar
• Matassov, D., Marzi, A., Latham, T., Xu, R., Ota-Setlik, A., Feldmann, F., … Clarke, D. K. (2015). Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus. The Journal of Infectious Diseases, 212(Suppl. 2), S443–S451. doi:10.1093/infdis/jiv31610.1093/infdis/jiv316
   PubMed Web of Science ®Google Scholar
• Maxmen, A. (2017, January 1). Ebola vaccine approved for use in ongoing outbreak. Retrieved 2017 from November 15.
   Google Scholar
• Mire, C. E., Matassov, D., Geisbert, J. B., Latham, T. E., Agans, K. N., Xu, R., … Geisbert, T. W. (2015). Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature, 520(7549), 688–691. doi:10.1038/nature14428
   PubMed Web of Science ®Google Scholar
• Mohammed, S., Bakshi, N., Chaudri, N., Akhter, J., & Akhtar, M. (2016). Cancer vaccines: Past, present, and future. Advances in Anatomic Pathology, 23(3), 180–191. doi:10.1097/PAP.0000000000000116
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. (2017, November 15). Cancer statistics. Retrieved from 2017, November 16.
   Google Scholar
• Obuchi, M., Fernandez, M., & Barber, G. N. (2003). Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. Journal of Virology, 77(16), 8843–8856.10.1128/JVI.77.16.8843-8856.2003
   PubMed Web of Science ®Google Scholar
• Pol, J. G., Zhang, L., Bridle, B. W., Stephenson, K. B., Rességuier, J., Hanson, S., … Lichty, B. D. (2014). Maraba virus as a potent oncolytic vaccine vector. Molecular Therapy : the Journal of the American Society of Gene Therapy, 22(2), 420–429. doi:10.1038/mt.2013.249
   PubMed Web of Science ®Google Scholar
• Prescott, J., DeBuysscher, B. L., Brown, K. S., & Feldmann, H. (2014). Long-term single-dose efficacy of a vesicular stomatitis virus-based andes virus vaccine in syrian hamsters. Viruses, 6(2), 516–523. doi:10.3390/v6020516
   PubMed Web of Science ®Google Scholar
• Pringle, C. R., Devine, V., Wilkie, M., Preston, C. M., Dolan, A., & McGeoch, D. J. (1981). Enhanced mutability associated with a temperature-sensitive mutant of vesicular stomatitis virus. Journal of Virology, 39(2), 377–389.
   PubMed Web of Science ®Google Scholar
• Publicover, J., Ramsburg, E., & Rose, J. K. (2004). Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. Journal of Virology, 78(17), 9317–9324. doi:10.1128/JVI.78.17.9317-9324.2004
   PubMed Web of Science ®Google Scholar
• Publicover, J., Ramsburg, E., & Rose, J. K. (2005). A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. Journal of Virology, 79(21), 13231–13238. doi:10.1128/JVI.79.21.13231-13238.2005
   PubMed Web of Science ®Google Scholar
• Ramsburg, E., Rose, N. F., Marx, P. A., Mefford, M., Nixon, D. F., Moretto, W. J., … Rose, J. K. (2004). Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. Journal of Virology, 78(8), 3930–3940. doi:10.1128/JVI.78.8.3930-3940.2004
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., … MOPH-TAVEG Investigators. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. The New England Journal of Medicine, 361(23), 2209–2220. doi:10.1056/NEJMoa0908492
   PubMed Web of Science ®Google Scholar
• Robert-Guroff, M. (2007). Replicating and non-replicating viral vectors for vaccine development. Current Opinion in Biotechnology, 18(6), 546–556. doi:10.1016/j.copbio.2007.10.010
   PubMed Web of Science ®Google Scholar
• Rommelfanger, D., Wongthida, P., Diaz, R. M., Kaluza, K. M., Thompson, J., Kottke, T., & Vile, R. G. (2012). Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T cell transfer. Cancer Research, 72(18), 4753–4764. doi:10.1158/0008-5472.CAN-12-0600
   PubMed Web of Science ®Google Scholar
• Rose, J. K., & Clarke, D. K. (2015). Rhabdoviruses as vaccine vectors. In Biology and Pathogenesis of Rhabdo- and Filoviruses, 199–230.
   Google Scholar
• Rose, N. F., Marx, P. A., Luckay, A., Nixon, D. F., Moretto, W. J., Donahoe, S. M., … Rose, J. K. (2001). An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell, 106(5), 539–549.10.1016/S0092-8674(01)00482-2
   PubMed Web of Science ®Google Scholar
• Rose, N. F., Roberts, A., Buonocore, L., & Rose, J. K. (2000). Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. Journal of Virology, 74(23), 10903–10910.10.1128/JVI.74.23.10903-10910.2000
   PubMed Web of Science ®Google Scholar
• Russell, S. J., Peng, K.-W., & Bell, J. C. (2012). Oncolytic virotherapy. Nature Biotechnology, 30(7), 658–670. doi:10.1038/nbt.2287
   PubMed Web of Science ®Google Scholar
• Ryder, A. B., Nachbagauer, R., Buonocore, L., Palese, P., Krammer, F., & Rose, J. K. (2015). Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains. Journal of Virology, 90(5), 2544–2550. doi:10.1128/JVI.02598-15
   PubMed Web of Science ®Google Scholar
• Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geisbert, T., & Feldmann, H. (2015). A recombinant vesicular stomatitis virus-based lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct lassa viruses. PLOS Neglected Tropical Diseases, 9(4), e0003736. doi:10.1371/journal.pntd.0003736
   PubMed Web of Science ®Google Scholar
• Schell, J. B., Rose, N. F., Bahl, K., Diller, K., Buonocore, L., Hunter, M., … Rose, J. K. (2011). Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. Journal of Virology, 85(12), 5764–5772. doi:10.1128/JVI.00342-11
   PubMed Web of Science ®Google Scholar
• Schell, J., Rose, N. F., Fazo, N., Marx, P. A., Hunter, M., Ramsburg, E., … Rose, J. K. (2009). Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine, 27(7), 979–986. doi:10.1016/j.vaccine.2008.12.01710.1016/j.vaccine.2008.12.017
   PubMed Web of Science ®Google Scholar
• Sharma, R., & Jangid, K., & Anuradha. (2017). Ebola vaccine: How far are we? Journal of Clinical and Diagnostic Research : JCDR, 11(5), DE01–DE04. doi:10.7860/JCDR/2017/22184.9863
   PubMed Web of Science ®Google Scholar
• Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., … Bell, J. C. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 4(4), 263–275.10.1016/S1535-6108(03)00241-1
   PubMed Web of Science ®Google Scholar
• UNAIDS. GLOBAL AIDS Update 2016. (2017, July 1). UNAIDS. GLOBAL AIDS Update 2016. Retrieved from 2017, November 17.
   Google Scholar
• Watson, J. C., Hadler, S. C., Dykewicz, C. A., Reef, S., & Phillips, L. (1998, May 22). Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). May 22, 1998 / 47(RR-8), 1–57.
   Google Scholar
• Wertz, G. W., Perepelitsa, V. P., & Ball, L. A. (1998). Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proceedings of the National Academy of Sciences of the United States of America, 95(7), 3501–3506.10.1073/pnas.95.7.3501
   PubMed Web of Science ®Google Scholar
• Wilson, R. A. M., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017). Immune checkpoint inhibitors: New strategies to checkmate cancer. Clinical and Experimental Immunology,. doi:10.1111/cei.13081
   PubMed Web of Science ®Google Scholar
• Wu, F., Fan, X., Yue, Y., Xiong, S., & Dong, C. (2014). A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine, 32(31), 3917–3926. doi:10.1016/j.vaccine.2014.05.052
   PubMed Web of Science ®Google Scholar
• Zhang, M., Dong, C., & Xiong, S. (2017). Vesicular stomatitis virus-vectored multi-antigen tuberculosis vaccine limits bacterial proliferation in mice following a single intranasal dose. Frontiers in Cellular and Infection Microbiology, 7, 1–9. doi:10.3389/fcimb.2017.00034
   PubMed Web of Science ®Google Scholar